C. Zuur (Lotje)

C. Zuur (Lotje)

Netherlands Cancer Institute - Amsterdam / Netherlands
Medical and Health Sciences / Otorhinolaryngology
AD Scientific Index ID: 4963270
Nederlands Kanker Instituut
person_outline C. Zuur (Lotje)'s MOST POPULAR ARTICLES
1-) Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2 … EA Rozeman, AM Menzies, ACJ van Akkooi, C Adhikari, C Bierman, ... The lancet oncology 20 (7), 948-960, 2019 2972019
2-) Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanomaEA Rozeman, EP Hoefsmit, ILM Reijers, RPM Saw, JM Versluis, ...Nature medicine 27 (2), 256-263, 20211882021
3-) Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trialILM Reijers, AM Menzies, ACJ Van Akkooi, JM Versluis, ...Nature medicine 28 (6), 1178-1188, 20221912022
4-) Concomitant radio- and fluorescence-guided sentinel lymph node biopsy in squamous cell carcinoma of the oral cavity using ICG-99mTc-nanocolloidNS van den Berg, OR Brouwer, WMC Klop, B Karakullukcu, CL Zuur, ...European journal of nuclear medicine and molecular imaging 39, 1128-1136, 20121882012
5-) Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinomaJL Vos, JBW Elbers, O Krijgsman, JJH Traets, X Qiao, AM van der Leun, ...Nature communications 12 (1), 7348, 20211742021